MedChemComm · 2010 · 25 citations · 26 references
MedicineMedicinal ChemistryPharmacologyCancer PharmacologyDrug DesignStructure-activity RelationshipsOncology PharmacologyPharmacodynamics Of Anticancer AgentsAnticancer ActivityAnticancer ChemotherapyAromatic Ring FeaturesAromatic Ring ReplacementBiological Activity FeaturesMedicinal HeterocyclesMolecular Conformation ControlSubstituent Effects On Biological Activity
The generally accepted view is that the 3,4,5-trimethoxy-substituted aromatic A-ring of combretastatin A-4 (CA-4) and its analogues should be conserved in order to maintain biological activity through enforcing an active molecular conformation. Contrary to this, we have found that substituting the larger meta-methoxy groups of CA-4 with smaller halogen atoms results in compounds that are equipotent or more potent than CA-4 itself in vitro.
26
Halogen bonds in biological molecules
Pascal Auffinger, Franklin A. Hays, Éric Westhof et al. · Proceedings of the National Academy of Sciences · 2004 · 1.6K citations · Full text
Halogen Bonding in Supramolecular Chemistry
Pierangelo Metrangolo, F. Meyer, Tullio Pilati et al. · Angewandte Chemie International Edition · 2008 · 1.6K citations
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
G. Dark, S A Hill, Vivien E. Prise et al. · PubMed · 1997 · 624 citations
Medicine, Oncology, Pharmacology +13
Halogen Bonding—A Novel Interaction for Rational Drug Design?
Yunxiang Lu, Ting Shi, Yong Wang et al. · Journal of Medicinal Chemistry · 2009 · 557 citations · Full text